Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844–7. https://doi.org/10.1111/jth.14768.
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan. China JAMA. 2020;323:1061–9. https://doi.org/10.1001/jama.2020.1585.
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–33. https://doi.org/10.1056/NEJMoa2001017.
Li WH, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–4. https://doi.org/10.1038/nature02145.
Mohammad A, Marafie SK, Alshawaf E, et al. Structural analysis of ACE2 variant N720D demonstrates a higher binding affinity to TMPRSS2. Life Sci. 2020. https://doi.org/10.1016/j.lfs.2020.118219.
Chung MK, Karnik S, Saef J, et al. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. Ebiomedicine. 2020. https://doi.org/10.1016/j.ebiom.2020.102907.
Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol. 2016;3:237–61. https://doi.org/10.1146/annurev-virology-110615-042301.
Han YX, Kral P. Computational design of ACE2-based peptide inhibitors of SARS-CoV-2. ACS Nano. 2020;14:5143–7. https://doi.org/10.1021/acsnano.0c02857.
Lambert DW, Yarski M, Warner FJ, et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem. 2005;280:30113–9. https://doi.org/10.1074/jbc.M505111200.
Haga S, Nagata N, Okamura T, et al. TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds. Antiviral Res. 2010;85:551–5. https://doi.org/10.1016/j.antiviral.2009.12.001.
Wang HL, Yang P, Liu KT, et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res. 2008;18:290–301. https://doi.org/10.1038/cr.2008.15.
Zhu XJ, Liu Q, Du LY, et al. Receptor-binding domain as a target for developing SARS vaccines. J Thorac Dis. 2013;5:S142–8. https://doi.org/10.3978/j.issn.2072-1439.2013.06.06.
Wu A, Peng Y, Huang B, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020;27:325–8. https://doi.org/10.1016/j.chom.2020.02.001.
Wan Y, Shang J, Graham R, et al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020. https://doi.org/10.1128/JVI.00127-20.
Zhou Y, Hou Y, Shen J, et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020;6:14. https://doi.org/10.1038/s41421-020-0153-3.
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–3. https://doi.org/10.1038/s41586-020-2012-7.
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–74. https://doi.org/10.1016/S0140-6736(20)30251-8.
Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63:457–60. https://doi.org/10.1007/s11427-020-1637-5.
Chung MK, Karnik S, Saef J, et al. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. EBioMedicine. 2020;58: 102907. https://doi.org/10.1016/j.ebiom.2020.102907.
Hoffmann M, Kleine-Weber H, Pohlmann S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol Cell. 2020;78:779-784 https://doi.org/10.1016/j.molcel.2020.04.022.
Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(281–292): e6. https://doi.org/10.1016/j.cell.2020.02.058.
Yang X, Yang W, McVey DG, et al. FURIN expression in vascular endothelial cells is modulated by a coronary artery disease-associated genetic variant and influences monocyte transendothelial migration. J Am Heart Assoc. 2020;9: e014333. https://doi.org/10.1161/JAHA.119.014333.
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052.
Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75:1564–81. https://doi.org/10.1111/all.14364.
Polidoro RB, Hagan RS, de Santis Santiago R, et al. Overview: systemic inflammatory response derived from lung injury caused by SARS-CoV-2 infection explains severe outcomes in COVID-19. Front Immunol. 2020;11:1626. https://doi.org/10.3389/fimmu.2020.01626.
Guo YR, Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7:11. https://doi.org/10.1186/s40779-020-00240-0.
Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–4. https://doi.org/10.1016/S0140-6736(20)30628-0.
Wang T, Chen RC, Liu CL, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol. 2020;7:E362–3. https://doi.org/10.1016/S2352-3026(20)30109-5.
Arachchillage DRJ, Laffan M. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:1233–4. https://doi.org/10.1111/jth.14820.
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20. https://doi.org/10.1056/NEJMoa2002032.
Osterholm MT. Preparing for the next pandemic. New Engl J Med. 2005;352:1839–42. https://doi.org/10.1056/NEJMp058068.
Sun XJ, Wang TY, Cai DY, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth F R. 2020;53:38–42. https://doi.org/10.1016/j.cytogfr.2020.04.002.
Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395:1763–70. https://doi.org/10.1016/S0140-6736(20)31189-2.
Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. 2020;72:1059–63. https://doi.org/10.1002/art.41285.
Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368:473–4. https://doi.org/10.1126/science.abb8925.
Lu L, Zhang H, Zhan M, et al. Preventing mortality in COVID-19 patients: which cytokine to target in a raging storm? Front Cell Dev Biol. 2020;8:677. https://doi.org/10.3389/fcell.2020.00677.
Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180:934–43. https://doi.org/10.1001/jamainternmed.2020.0994.
Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39:529–39. https://doi.org/10.1007/s00281-017-0629-x.
Zhou X, Wang G, Chen L, et al. Clinical characteristics of hematological patients concomitant with COVID-19. Cancer Sci. 2020;111:3379–85. https://doi.org/10.1111/cas.14544.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.
Mahmudpour M, Roozbeh J, Keshavarz M, et al. COVID-19 cytokine storm: the anger of inflammation. Cytokine. 2020;133: 155151. https://doi.org/10.1016/j.cyto.2020.155151.
Miossec P. Synergy between cytokines and risk factors in the cytokine storm of COVID-19: does ongoing use of cytokine inhibitors have a protective effect? Arthr Rheumatol. 2020;72:1963–6. https://doi.org/10.1002/art.41458.
Panigrahy D, Gilligan M, Huang S, et al. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19? Cancer Metastasis Rev. 2020;39:337–40. https://doi.org/10.1007/s10555-020-09889-4.
Li J, Guo M, Tian X, et al. Virus-host interactome and proteomic survey reveal potential virulence factors influencing SARS-CoV-2 pathogenesis. Med (N Y). 2021;2(99–112): e7. https://doi.org/10.1016/j.medj.2020.07.002.
Ye Q, Wang BL, Mao JH. The pathogenesis and treatment of the “Cytokine Storm” in COVID-19. J Infection. 2020;80:607–13. https://doi.org/10.1016/j.jinf.2020.03.037.
Zhang R, Wang XB, Ni L, et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci. 2020;250: 117583. https://doi.org/10.1016/j.lfs.2020.117583.
Yang XB, Yu Y, Xu JQ, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Resp Med. 2020;8:475–81. https://doi.org/10.1016/S2213-2600(20)30079-5.
Quirch M, Lee J, Rehman S. Hazards of the cytokine storm and cytokine-targeted therapy in patients with COVID-19: review. J Med Internet Res. 2020;22: e20193. https://doi.org/10.2196/20193.
Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71:762–8. https://doi.org/10.1093/cid/ciaa248.
Kiselevskiy M, Shubina I, Chikileva I, et al. Immune pathogenesis of COVID-19 intoxication: storm or silence? Pharmaceuticals (Basel). 2020;13:166. https://doi.org/10.3390/ph13080166.
Tang Y, Liu J, Zhang D, et al. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol. 2020;11:1708. https://doi.org/10.3389/fimmu.2020.01708.
Wan SX, Yi QJ, Fan SB, et al. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Brit J Haematol. 2020;189:428–37. https://doi.org/10.1111/bjh.16659.
Xu B, Fan CY, Wang AL, et al. Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan. China J Infection. 2020;81:E51–60. https://doi.org/10.1016/j.jinf.2020.04.012.
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–2. https://doi.org/10.1016/S2213-2600(20)30076-X.
Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect. 2020;9:761–70. https://doi.org/10.1080/22221751.2020.1747363.
Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620–9. https://doi.org/10.1172/Jci137244.
Wang ZF, Zhang AL, Wan YM, et al. Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. P Natl Acad Sci USA. 2014;111:769–74. https://doi.org/10.1073/pnas.1321748111.
Li C, Yang P, Zhang Y, et al. Corticosteroid treatment ameliorates acute lung injury induced by 2009 swine origin influenza A (H1N1) virus in mice. PLoS ONE. 2012;7: e44110. https://doi.org/10.1371/journal.pone.0044110.
Younan P, Iampietro M, Nishida A, et al. Ebola virus binding to Tim-1 on T lymphocytes induces a cytokine storm. MBio. 2017;8:e00845-e917. https://doi.org/10.1128/mBio.00845-17.
Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Military Med Res. 2020;7:4. https://doi.org/10.1186/s40779-020-0233-6.
Calabrese LH. Cytokine storm and the prospects for immunotherapy with COVID-19. Cleve Clin J Med. 2020;87:389–93. https://doi.org/10.3949/ccjm.87a.ccc008.
Zhou W, Liu Y, Tian D, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020. https://doi.org/10.1038/s41392-020-0127-9.
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13. https://doi.org/10.1016/S0140-6736(20)30211-7.
Yang Z, Liu J, Zhou Y, et al. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect. 2020;81:e13–20. https://doi.org/10.1016/j.jinf.2020.03.062.
Mahmud-Al-Rafat A, Majumder A, Rahman KMT, et al. Decoding the enigma of antiviral crisis: does one target molecule regulate all? Cytokine. 2019;115:13–23. https://doi.org/10.1016/j.cyto.2018.12.008.
Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–5. https://doi.org/10.1016/s0140-6736(20)30317-2.
Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20:400–2. https://doi.org/10.1016/S1473-3099(20)30132-8.
Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:E30–1. https://doi.org/10.1016/S0140-6736(20)30304-4.
Favalli EG, Biggioggero M, Maioli G, et al. Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis. 2020;20:1012–3. https://doi.org/10.1016/S1473-3099(20)30262-0.
Gendelman O, Amital H, Bragazzi NL, et al. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis. Autoimmun Rev. 2020;19: 102566. https://doi.org/10.1016/j.autrev.2020.102566.
Cumhur Cure M, Kucuk A, Cure E. Colchicine may not be effective in COVID-19 infection; it may even be harmful? Clin Rheumatol. 2020;39:2101–2. https://doi.org/10.1007/s10067-020-05144-x.
Zheng F, Liao C, Fan QH, et al. Clinical characteristics of children with coronavirus disease 2019 in Hubei, China. Curr Med Sci. 2020;40:275–80. https://doi.org/10.1007/s11596-020-2172-6.
Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117:10970–5. https://doi.org/10.1073/pnas.2005615117.
Noris M, Remuzzi G. Overview of complement activation and regulation. Semin Nephrol. 2013;33:479–92. https://doi.org/10.1016/j.semnephrol.2013.08.001.
Noris M, Benigni A, Remuzzi G. The case of complement activation in COVID-19 multiorgan impact. Kidney Int. 2020;98:314–22. https://doi.org/10.1016/j.kint.2020.05.013.
Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov. 2019;18:707–29. https://doi.org/10.1038/s41573-019-0031-6.
Spear GT, Hart M, Olinger GG, et al. The role of the complement system in virus infections. Curr Top Microbiol Immunol. 2001;260:229–45. https://doi.org/10.1007/978-3-662-05783-4_12.
Guo RF, Ward PA. Role of C5A in inflammatory responses. Annu Rev Immunol. 2005;23:821–52. https://doi.org/10.1146/annurev.immunol.23.021704.115835.
Huang JL, Huang J, Duan ZH, et al. Th2 predominance and CD8+ memory T cell depletion in patients with severe acute respiratory syndrome. Microbes Infect. 2005;7:427–36. https://doi.org/10.1016/j.micinf.2004.11.017.
Gao T, Hu M, Zhang X, et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. MedRxiv. 2020. https://doi.org/10.1101/2020.03.29.20041962.
Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1–13. https://doi.org/10.1016/j.trsl.2020.04.007.
Chaturvedi S, Braunstein EM, Yuan X, et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2020;135:239–51. https://doi.org/10.1182/blood.2019003863.
Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infec. 2020;9:761–70. https://doi.org/10.1080/22221751.2020.1747363.
Zhang XH, Kimura Y, Fang CY, et al. Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood. 2007;110:228–36. https://doi.org/10.1182/blood-2006-12-063636.
Hawlisch H, Belkaid Y, Baelder R, et al. C5a negatively regulates toll-like receptor 4-induced immune responses. Immunity. 2005;22:415–26. https://doi.org/10.1016/j.immuni.2005.02.006.
Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20:269–70. https://doi.org/10.1038/s41577-020-0308-3.
Kwan WH, van der Touw W, Paz-Artal E, et al. Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells. J Exp Med. 2013;210:257–68. https://doi.org/10.1084/jem.20121525.
Kim AHJ, Dimitriou ID, Holland MCH, et al. Complement C5a receptor is essential for the optimal generation of antiviral CD8(+) T cell responses. J Immunol. 2004;173:2524–9. https://doi.org/10.4049/jimmunol.173.4.2524.
Yousefi S, Mihalache C, Kozlowski E, et al. Viable neutrophils release mitochondrial DNA to form neutrophil extracellular traps. Cell Death Differ. 2009;16:1438–44. https://doi.org/10.1038/cdd.2009.96.
Cole DS, Morgan BP. Beyond lysis: how complement influences cell fate. Clin Sci. 2003;104:455–66. https://doi.org/10.1042/cs20020362.
Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20:34–50. https://doi.org/10.1038/cr.2009.139.
Twaddell SH, Baines KJ, Grainge C, et al. The emerging role of neutrophil extracellular traps in respiratory disease. Chest. 2019;156:774–82. https://doi.org/10.1016/j.chest.2019.06.012.
Narasaraju T, Yang E, Samy RP, et al. Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis. Am J Pathol. 2011;179:199–210. https://doi.org/10.1016/j.ajpath.2011.03.013.
Porto BN, Stein RT. Neutrophil extracellular traps in pulmonary diseases: too much of a good thing? Front Immunol. 2016;7:311. https://doi.org/10.3389/fimmu.2016.00311.
Tomar B, Anders HJ, Desai J, et al. Neutrophils and neutrophil extracellular traps drive necroinflammation in COVID-19. Cells-Basel. 2020;9:1383. https://doi.org/10.3390/cells9061383.
Jorch SK, Kubes P. An emerging role for neutrophil extracellular traps in noninfectious disease. Nat Med. 2017;23:279–87. https://doi.org/10.1038/nm.4294.
Kessenbrock K, Krumbholz M, Schonermarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15:623–5. https://doi.org/10.1038/nm.1959.
Papayannopoulos V, Metzler KD, Hakkim A, et al. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol. 2010;191:677–91. https://doi.org/10.1083/jcb.201006052.
Ritis K, Doumas M, Mastellos D, et al. A novel c5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol. 2006;177:4794–802. https://doi.org/10.4049/jimmunol.177.7.4794.
Chauhan AJ, Wiffen LJ, Brown TP. COVID-19: A collision of complement, coagulation and inflammatory pathways. J Thromb Haemost. 2020;18:2110–7. https://doi.org/10.1111/jth.14981.
Beltrame MH, Catarino SJ, Goeldner I, et al. The lectin pathway of complement and rheumatic heart disease. Front Pediatr. 2014;2:148. https://doi.org/10.3389/fped.2014.00148.
Krarup A, Wallis R, Presanis JS, et al. Simultaneous activation of complement and coagulation by MBL-associated serine protease 2. PLoS ONE. 2007;2: e623. https://doi.org/10.1371/journal.pone.0000623.
Magro CM, Momtahen S, Mulvey JJ, et al. Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome. Am J Dermatopathol. 2015;37:349–56. https://doi.org/10.1097/DAD.0000000000000234 (quiz 357-9).
Wang RX, Xiao H, Guo RF, et al. The role of C5a in acute lung injury induced by highly pathogenic viral infections. Emerg Microbes Infec. 2015;4: e28. https://doi.org/10.1038/emi.2015.28.
Ward PA. New strategies for treatment of humans with acute lung injury/acute respiratory distress syndrome. Clin Infect Dis. 2015;60:596–7. https://doi.org/10.1093/cid/ciu892.
Gralinski LE, Sheahan TP, Morrison TE, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. MBio. 2018;9:e01753-e1818. https://doi.org/10.1128/mBio.01753-18.
Risitano AM, Mastellos DC, Huber-Lang M, et al. Complement as a target in COVID-19? Nat Rev Immunol. 2020;20:343–4. https://doi.org/10.1038/s41577-020-0320-7.
Soy M, Keser G, Atagunduz P, et al. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol. 2020;39:2085–94. https://doi.org/10.1007/s10067-020-05190-5.
Jiang YT, Zhao GY, Song NP, et al. Blockade of the C5a–C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018;7:77. https://doi.org/10.1038/s41426-018-0063-8.
Mastaglio S, Ruggeri A, Risitano AM, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020;215: 108450. https://doi.org/10.1016/j.clim.2020.108450.
Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117:6786–92. https://doi.org/10.1182/blood-2011-02-333997.
Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. New Engl J Med. 2019;381:614–25. https://doi.org/10.1056/NEJMoa1900866.
Diurno F, Numis FG, Porta G, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmaco. 2020;24:4040–7. https://doi.org/10.26355/eurrev_202004_20875.
Ormsby R, Jokiranta T, Duthy T, et al. Localization of the third heparin-binding site in the human complement regulator factor. Mol Immunol. 2006;H1(43):1624–32. https://doi.org/10.1016/j.molimm.2005.09.012.
Fan H, Liu F, Bligh SW, et al. Structure of a homofructosan from Saussurea costus and anti-complementary activity of its sulfated derivatives. Carbohydr Polym. 2014;105:152–60. https://doi.org/10.1016/j.carbpol.2014.01.084.
Wang H, Wang H, Shi S, et al. Structural characterization of a homogalacturonan from Capparis spinosa L. fruits and anti-complement activity of its sulfated derivative. Glycoconj J. 2012;29:379–87. https://doi.org/10.1007/s10719-012-9418-x.
Fu ZL, Xia L, De J, et al. Beneficial effects on H1N1-induced acute lung injury and structure characterization of anti-complementary acidic polysaccharides from Juniperus pingii var. wilsonii. Int J Biol Macromol. 2019;129:246–53. https://doi.org/10.1016/j.ijbiomac.2019.01.163.
Xu YY, Zhang YY, Ou YY, et al. Houttuynia cordata Thunb. polysaccharides ameliorates lipopolysaccharide-induced acute lung injury in mice. J Ethnopharmacol. 2015;173:81–90. https://doi.org/10.1016/j.jep.2015.07.015.
Lu Y, Jiang Y, Ling LJ, et al. Beneficial effects of Houttuynia cordata polysaccharides on “two-hit” acute lung injury and endotoxic fever in rats associated with anti-complementary activities. Acta Pharm Sin B. 2018;8:218–27. https://doi.org/10.1016/j.apsb.2017.11.003.
Cheng XQ, Song LJ, Li H, et al. Beneficial effect of the polysaccharides from Bupleurum smithii var. parvifolium on “two-hit” acute lung injury in rats. Inflammation. 2012;35:1715–22. https://doi.org/10.1007/s10753-012-9489-7.
Xie JY, Di HY, Li H, et al. Bupleurum chinense DC polysaccharides attenuates lipopolysaccharide-induced acute lung injury in mice. Phytomedicine. 2012;19:130–7. https://doi.org/10.1016/j.phymed.2011.08.057.
Zhi HJ, Zhu HY, Zhang YY, et al. In vivo effect of quantified flavonoids-enriched extract of Scutellaria baicalensis root on acute lung injury induced by influenza A virus. Phytomedicine. 2019;57:105–16. https://doi.org/10.1016/j.phymed.2018.12.009.
Zhang Q, Li CS, Wang S, et al. Effects of Chinese medicine shen-fu injection on the expression of inflammatory cytokines and complements during post-resuscitation immune dysfunction in a porcine model. Chin J Integr Med. 2016;22:101–9. https://doi.org/10.1007/s11655-014-1857-8.
Ren W, Liang P, Ma Y, et al. Research progress of traditional Chinese medicine against COVID-19. Biomed Pharmacother. 2021;137: 111310. https://doi.org/10.1016/j.biopha.2021.111310.
Zhang BL, Wang YY. Basic research on key scientific problems of Chinese medicine prescriptions–development of modern Chinese medicine by compatibility of components. Chin J Nat Med. 2005;3:258–61.
Xiao XH, Yan D, Yuan HL, et al. A model for identification and quality control of active components of traditional Chinese medicine based on component knock-out/knock-in. Chin Tradit Herbal Drugs. 2009;40:1345–8.
Huang X, Kong L, Li X, et al. Strategy for analysis and screening of bioactive compounds in traditional Chinese medicines. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;812:71–84. https://doi.org/10.1016/j.jchromb.2004.06.046.
Zhang AH, Sun H, Yan GL, et al. Chinmedomics: a powerful approach integrating metabolomics with serum pharmacochemistry to evaluate the efficacy of traditional Chinese medicine. Engineering-Prc. 2019;5:60–8. https://doi.org/10.1016/j.eng.2018.11.008.
Chen C, Yang FQ, Zuo HL, et al. Applications of biochromatography in the screening of bioactive natural products. J Chromatogr Sci. 2013;51:780–90. https://doi.org/10.1093/chromsci/bmt002.
Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med. 2013;11:110–20. https://doi.org/10.1016/S1875-5364(13)60037-0.
Xue X, Jiao Q, Jin R, et al. The combination of UHPLC-HRMS and molecular networking improving discovery efficiency of chemical components in Chinese Classical Formula. Chin Med. 2021;16:50. https://doi.org/10.1186/s13020-021-00459-6.
Li ZX, Zhao GD, Xiong W, et al. Correction to: Immunomodulatory effects of a new whole ingredients extract from Astragalus: a combined evaluation on chemistry and pharmacology. Chin Med. 2021;16:38. https://doi.org/10.1186/s13020-021-00440-3.
Ou YY, Jiang Y, Li H, et al. Polysaccharides from Arnebia euchroma ameliorated endotoxic fever and acute lung injury in rats through inhibiting complement system. Inflammation. 2017;40:275–84. https://doi.org/10.1007/s10753-016-0478-0.
Zhi HW, Zhang YY, Zhang JW, et al. Isolation and characterization of an anti-complementary protein-bound polysaccharide from the stem barks of Eucommia ulmoides. Int Immunopharmacol. 2008;8:1222–30. https://doi.org/10.1016/j.intimp.2008.04.012.
Xia L, Li BB, Lu Y, et al. Structural characterization and anticomplement activity of an acidic polysaccharide containing 3-O-methyl galactose from Juniperus tibetica. Int J Biol Macromol. 2019;132:1244–51. https://doi.org/10.1016/j.ijbiomac.2019.04.029.
Xia L, Zhu MX, et al. Juniperus pingii var. wilsonii acidic polysaccharide: extraction, characterization and anticomplement activity. Carbohyd Polym. 2020;231:115728. https://doi.org/10.1016/j.carbpol.2019.115728.
Zhu T, Wang DX, Zhang W, et al. Andrographolide protects against LPS-induced acute lung injury by inactivation of NF-kappaB. PLoS ONE. 2013;8: e56407. https://doi.org/10.1371/journal.pone.0056407.
Coon JT, Ernst E. Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy. Planta Med. 2004;70:293–8. https://doi.org/10.1055/s-2004-818938.
Wen Q, Jin X, Lu Y, et al. Anticomplement ent-labdane diterpenoids from the aerial parts of Andrographis paniculata. Fitoterapia. 2020;142: 104528. https://doi.org/10.1016/j.fitote.2020.104528.